Thomas Lingelbach, Valneva CEO

Once promis­ing an al­ter­na­tive shot, Val­neva's Covid-19 sup­ply deal with Eu­rope on verge of col­lapse

When French vac­cine mak­er Val­ne­va signed a pur­chase agree­ment with the Eu­ro­pean Com­mis­sion in No­vem­ber, ex­ecs tout­ed how the deal — un­der which it would sup­ply 60 mil­lion dos­es of its in­ac­ti­vat­ed, ad­ju­vant­ed whole-virus Covid-19 vac­cine — of­fered an al­ter­na­tive to the mR­NA and ade­n­ovirus-based shots al­ready out there.

But the whole deal may be in jeop­ardy now.

The EC first sent a no­tice of in­tent to ter­mi­nate the pur­chase agree­ment back in May, as the reg­u­la­to­ry re­view of Val­ne­va’s vac­cine stalled. De­spite propos­ing a re­me­di­a­tion plan, Val­ne­va dis­closed Fri­day that the lat­est dis­cus­sions sug­gest the chances of reach­ing a re­vised deal are slim.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.